Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Conditions
/ KRAS Gene Mutation
KRAS Gene Mutation
17 registered clinical trials studyying KRAS Gene Mutation.
Status
Trial
Sponsor
Phase
Terminated
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
NCT04965818
Taiho Oncology, Inc.
Phase 1
Active Not Recruiting
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
NCT03808558
David E Gerber
Phase 2
Terminated
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in
NCT03777124
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
Completed
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
NCT03965845
Calithera Biosciences, Inc
Phase 1 / Phase 2
Completed
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Can
NCT03829410
Cardiff Oncology
Phase 1 / Phase 2
Completed
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
NCT03704688
Memorial Sloan Kettering Cancer Center
Phase 1 / Phase 2
Completed
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell
NCT03520842
Stanford University
Phase 2
Completed
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutat
NCT03299088
Jonathan Riess
Phase 1
Completed
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
NCT03750175
Karen-Lise Garm Spindler
—
Active Not Recruiting
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT03087071
M.D. Anderson Cancer Center
Phase 2
Active Not Recruiting
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or
NCT03065387
M.D. Anderson Cancer Center
Phase 1
Completed
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
NCT02964689
Swiss Cancer Institute
Phase 1
Active Not Recruiting
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell
NCT02642042
National Cancer Institute (NCI)
Phase 2
Completed
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients
NCT03171636
Hospital Erasto Gaertner
—
Completed
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
NCT01700582
Intergroupe Francophone de Cancerologie Thoracique
—
Completed
I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutati
NCT02818725
UNICANCER
Phase 3
No Longer Available
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With
NCT04446793
Cardiff Oncology
—